A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Trial Profile

A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Merck
  • Most Recent Events

    • 19 Jan 2018 Planned primary completion date changed from 20 Jan 2018 to 6 Feb 2018.
    • 11 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Apr 2017 Results assessing the presence of Merkel cell polyomavirus as predictor of response to pembrolizumab, presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top